European Association for the Study of Diabetes

47th EASD Annual Meeting | September 12-16, 2011 - Lisbon, Portugal

Note that some of these links take you to a site outside of CardioSource.
CardioSource does not assume responsibility for content of external sites.

Gliptin Tx Works Long-Term for Glycemic Control

LISBON — Long-term treatment of type 2 diabetes with dipeptidyl peptidase-4 (DPP-4) inhibitors for two years appeared to maintain improvement in glycosylated hemoglobin A1c levels, researchers reported here.
- Read More

Breast Cancer in Diabetes May Be Artifactual

LISBON — An apparent risk of breast cancer in postmenopausal women recently diagnosed with type 2 diabetes may in fact be related to detection bias, researchers reported here.
- Read More
'Gliptin' Diabetes Drugs May Be Heart Savers

LISBON — While searching for potential cardiovascular risks among studies involving dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetics, researchers made a surprising discovery -- treatment with the so-called gliptin class appears to protect the heart.
- Read More
Novel Drug BRIGHTENs Diabetes Research

LISBON — The investigational drug ipragliflozin improved glycemic control and decreased body weight and blood pressure, according to the phase III BRIGHTEN study.
- Read More

Once-Weekly Exenatide Flops Against Liraglutide

LISBON — A trial failed to prove that once-weekly injections of exenatide (Bydureon) were equal to daily injections of liraglutide (Victoza) in reducing glycosylated hemoglobin A1c in type 2 diabetes patients, researchers reported here.
- Read More
No Microvascular Benefit With Intense BP, Glucose Control

LISBON — Aggressively lowering blood pressure and blood glucose together won't provide any microvascular benefits to type 2 diabetes patients, researchers said here.
- Read More
Biomarkers May Predict CAD, Death in Diabetics

LISBON — Two biomarkers may be associated with cardiovascular events and death in type 2 diabetes patients, researchers reported here.
- Read More

Liraglutide Plus Insulin Does Not Add Weight

LISBON — The addition of insulin to the treatment regimen of type 2 diabetes patients on liraglutide (Victoza) doesn't wipe out previously seen weight loss — and insulin appears to help these patients achieve glycemic control, researchers said here.
- Read More
Gestational Diabetes Guidelines Controversial

LISBON — International guidelines on screening for gestational diabetes that will raise the prevalence of the condition have sparked questions over appropriate diagnostic tools and cost efficacy, researchers said here.
- Read More
Intensive Glucose Control Cuts Renal Risks

LISBON — Intensive glucose-lowering may protect against end-stage renal disease (ESRD) in diabetic patients, according to an analysis of data from the ADVANCE trial.
- Read More

Diabetes, MI, Feeling Bad Add Up to Shorter Life

LISBON — Men with type 2 diabetes and an acute myocardial infarction who score lower on quality-of-life measures have a greater mortality risk than other men with these conditions whose scores indicate they feel better about their health, researchers reported here.
- Read More

Hot Controversies, but No Hot-Line Sizzlers

LISBON — Though there's "no major endpoint trial" being presented at this year's European Association for the Study of Diabetes meeting here, executive director Viktor Joergens, MD, said there will be plenty of debate over several recent controversies.
- Read More